The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

As more research is published about the health benefits associated with GLP-1s, like sleep apnea, heart disease, and ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.

Though the big game has long been hallowed ground for some of the most entertaining and memorable commercials, they often don ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

According to Sarah Marjoram, MS, RDN, a dietitian who specializes in food as medicine, “When it comes to improving health, ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Telehealth company Him & Hers Health is taking a very different approach to its Super Bowl ad this year - as its new ...